에큐렉스 파마슈티컬스(ACXP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.39 (+0.00%), 시가총액 $0.01B, 52주 최저~최고 $0.29 ~ $8.10.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 a
에큐렉스 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
에큐렉스 파마슈티컬스의 현재 주가는 $1.39 (+0.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
에큐렉스 파마슈티컬스의 시가총액은 약 $0.01B입니다.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolsta